STOCK TITAN
  1. Home
  2. News
  3. SLN

Silence Therapeutics Plc - SLN STOCK NEWS

Welcome to our dedicated news page for Silence Therapeutics Plc (Ticker: SLN), a resource for investors and traders seeking the latest updates and insights on Silence Therapeutics Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Silence Therapeutics Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Silence Therapeutics Plc's position in the market.

News
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)
Rhea-AI Summary
Silence Therapeutics plc, Nasdaq: SLN, announced positive results from the APOLLO phase 1 study of zerlasiran in reducing Lp(a) levels, a genetic risk factor for cardiovascular disease. The findings, published in JAMA, show sustained reductions in Lp(a) concentrations with well-tolerated profiles, promising advancements in addressing cardiovascular disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
clinical trial
-
News
Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
Rhea-AI Summary
Silence Therapeutics plc, Nasdaq: SLN, reported positive topline 36-week data from an ongoing phase 2 study of zerlasiran in patients with high lipoprotein(a). The company also disclosed its financial results for the full year ended December 31, 2023, and highlighted recent business achievements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
earnings
-
News
Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)
Rhea-AI Summary
Silence Therapeutics plc (SLN) announced positive topline 36-week data from the ALPACAR-360 phase 2 study of zerlasiran for reducing Lp(a) levels in high-risk ASCVD patients. Zerlasiran demonstrated a highly significant reduction in Lp(a) levels, with a median percentage reduction of 90% or greater at week 36. Topline 48-week data is expected in 2Q 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
clinical trial
News
Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024
Rhea-AI Summary
Silence Therapeutics plc, Nasdaq: SLN, will release its financial and business results for Q4 and full year 2023 on March 13, 2024. The company will host a conference call to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
conferences earnings
-
News
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial
Rhea-AI Summary
Silence Therapeutics (SLN) announces a $10 million milestone payment from AstraZeneca for the initiation of a phase 1 clinical trial under their siRNA collaboration. This marks the first clinical milestone under their partnership and the third program to enter the clinic from their mRNAi GOLD™ platform. The collaboration aims to develop innovative therapies for cardiovascular, renal, metabolic, and respiratory diseases, with potential milestone payments of up to $140 million in development and $250 million in commercialization, along with tiered royalties on net sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
clinical trial
-
News
Silence Therapeutics Announces Oversubscribed $120 Million Private Placement
Rhea-AI Summary
Silence Therapeutics plc (SLN) announced an oversubscribed private placement of 5,714,286 of the Company’s American Depositary Shares at a purchase price of US $21.00 per ADS, representing a premium of approximately 11% to Silence’s 30-day volume-weighted average price. The aggregate gross proceeds of the Private Placement are expected to be approximately US $120.0 million before deducting placement agent fees and other offering expenses. Investors in the Private Placement include 5AM Ventures, Frazier Life Sciences, Logos Capital, Nextech Invest Ltd, Redmile Group, TCGX, and Vivo Capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.86%
Tags
none
News
Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Rhea-AI Summary
Silence Therapeutics plc, Nasdaq: SLN, will participate in a fireside chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on February 7th. The live webcast can be accessed via the Investors section of the Silence website. An archived replay of the webcast will be available following the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.44%
Tags
conferences
-
News
Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments
Rhea-AI Summary
Silence Therapeutics plc (Nasdaq: SLN) promotes Curtis Rambaran, MD to Chief Medical Officer and Marie Wikström Lindholm, PhD to Chief Scientific Officer. Both have been instrumental to the company's clinical and scientific successes. Curtis' experience in leading successful early and late-stage development programs combined with his background in cardiovascular medicine will be invaluable to Silence's next phase of growth. Marie's extensive work in oligonucleotide therapeutics is impressive, and the company looks forward to her leading their efforts to innovate and further expand their footprint as a global siRNA leader.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.28%
Tags
management
-
News
Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Silence Therapeutics plc (Nasdaq: SLN) reported strong execution across its mRNAi GOLD™ platform, including positive data from the multiple dose study for zerlasiran in patients with high Lp(a) and stable ASCVD, and progress in the SLN124 phase 1/2 study in polycythemia vera. The company also reviewed recent business highlights and financial results for the third quarter ended September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.33%
Tags
earnings
News
Silence Therapeutics to Present at Jefferies London Healthcare Conference
Rhea-AI Summary
Silence Therapeutics plc (Nasdaq: SLN) announced that Craig Tooman, President and CEO, will present a corporate update at the Jefferies London Healthcare Conference on November 15th. The webcast can be accessed via the Investors section of the Silence website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.49%
Tags
conferences
Stock SLN logo
Silence Therapeutics Plc

Nasdaq:SLN

SLN Rankings

#2409 Ranked by Market Cap
#4247 Ranked by Stock Gains
N/A Ranked by Dividends

SLN Stock Data

1.10B
72.78M
16.99%
44.6%
0.35%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
UK
London

About SLN

silence therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of rna interference, or rnai, within its cells. our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic rna molecules exclusively to target cells. silence’s proprietary rna chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. for more information, visit us at www.silence-therapeutics.com